Artelo Biosciences, Inc.
ARTL
$6.04
-$0.16-2.50%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.63M | 1.92M | 1.89M | 1.81M | 1.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.51M | 2.69M | 2.79M | 3.09M | 3.15M |
| Operating Income | -2.51M | -2.69M | -2.79M | -3.09M | -3.15M |
| Income Before Tax | -2.43M | -2.96M | -4.17M | -3.12M | -3.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.43M | -2.96M | -4.17M | -3.12M | -3.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.43M | -2.96M | -4.17M | -3.12M | -3.22M |
| EBIT | -2.51M | -2.69M | -2.79M | -3.09M | -3.15M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -8.05 | -36.02 | -55.63 | -107.04 | -151.78 |
| Normalized Basic EPS | -5.12 | -22.52 | -25.29 | -66.90 | -94.86 |
| EPS Diluted | -8.05 | -36.02 | -55.63 | -107.04 | -151.78 |
| Normalized Diluted EPS | -5.12 | -22.52 | -25.29 | -66.90 | -94.86 |
| Average Basic Shares Outstanding | 301.30K | 82.10K | 74.90K | 29.10K | 21.20K |
| Average Diluted Shares Outstanding | 301.30K | 82.10K | 74.90K | 29.10K | 21.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |